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Abstract
Drug-induced ototoxicity has been known for centuries. Already in the seventeenth 
century, hearing loss was described to be a side effect of quinine. The post- World War 
II pharmaceutical industry boomed with the production of aminoglycoside antibiotics 
followed by diuretics and cytostatic drugs. Wide-spread and long-term usage of these 
medications brought the knowledge about their unwanted ototoxic effects. In the last 
decades, several new drugs appeared on the shelves of pharmacies and the hearing loss 
or tinnitus have been among the side effects of many of them. However, the awareness 
of community about new ototoxic medications is still not sufficient. New ototoxic drugs 
may belong to the class of phosphodiesterase-5 (PDE5) inhibitors, used to improve 
microcirculation and to treat erectile dysfunction. Moreover, interferons used for the 
therapy of hepatitis B and C, common painkiller paracetamol and hydrocodone, syn-
thetic opioid methadone and the inhibitors of reverse transcriptase were demonstrated 
to induce adverse effects on hearing. Lastly, hearing loss linked to immunosuppres-
sive drugs was documented in patients undergoing organ transplantation. Making the 
patients aware of adverse drug reactions and offering them audiological monitoring and 
intervention should be considered by respective therapists.
Keywords: ototoxic drugs, viral infections, reverse transcriptase inhibitors, interferons, 
PDE5 inhibitors, immunosuppressants, hearing loss, adverse reactions
1. Introduction
The sense of hearing is fundamental to the communication and proper reaction to dan-
gerous situations. Moreover, recent studies indicated that the hearing loss increases sig-
nificantly the risk of dementia [1]. Unfortunately, people’s ability to hear deteriorates with 
time, as the human auditory epithelium is post-mitotic and unable to regenerate. In other 
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words, the few thousand of auditory hair cells with which we are born have to last our 
entire life. There are several causes of hearing loss such as noise, aging, infections, tumors, 
neuronal degeneration or cardiovascular diseases. Another important cause of hearing loss 
is ototoxicity.
In this chapter, we will concentrate on medications that are known to induce hearing loss as 
an adverse effect. These medications are also known as ototoxic medications.
Clinical signs of ototoxicity may include at least one of the following symptoms:
• tinnitus
• hearing loss (unilateral or bilateral)
• vertigo.
First signs of ototoxicity usually develop during or shortly after receiving particular medi-
cation. Majority of ototoxic drugs induces irreparable damage translating into permanent 
hearing loss; however, aspirin and derivatives belong to drugs that cause most of the times 
reversible hearing loss [2]. In fact, aspirin-induced ototoxicity in form of tinnitus was used 
for decades by rheumatologists to adjust the maximal therapeutic dose of salicylates in the 
patients. This practice was abandoned because of poor correlation between salicylate blood 
levels and ototoxicity symptoms [3] and because of development of new drugs used for the 
treatment of rheumatic diseases. Nevertheless, even today there are patients occasionally 
admitted to the emergency room because of the salicylate-induced ototoxicity [4]. The ototox-
icity of salicylate has been attributed to its capacity to bind and inhibit the action of cochlear 
protein prestin, expressed by the outer hair cells [5, 6]. In addition, salicylate can induce 
death of spiral ganglion neurons as well as cause dysregulation in the central auditory 
pathway [7].
Other groups of well-known ototoxic drugs that frequently cause hearing loss include:
• platinum-based cytostatic drugs
• aminoglycoside antibiotics
• loop diuretics
Platinum-based cytostatics (cisplatin, carboplatin and oxaliplatin) are used as single agents 
and in combination with other drugs for the treatment of various types of cancer (e.g., testicu-
lar carcinoma, lung carcinoma, ovarian carcinoma, head and neck carcinomas,  melanomas, 
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lymphomas and neuroblastomas) [8]. The platinum-based drugs bind DNA and induce irre-
versible changes that prohibit tumor cell division. However, common adverse effects of plat-
inum-based drugs include nephrotoxicity and ototoxicity. This toxicity is being attributed to 
an excessive production of reactive oxygen species that leads to death of auditory hair cells 
[9–11]. Clinically, patients develop permanent bilateral hearing loss that originates in high 
frequencies [12]. In addition, patients may have difficulties with speech understanding in 
noise [13].
Aminoglycosides are a group of antibiotics used to treat gram-negative bacterial and 
mycobacterial infections. Clinically used aminoglycosides include amikacin and kana-
mycin (primarily cochleotoxic) as well as gentamicin, streptomycin and tobramycin (pri-
marily vestibulotoxic) [14]. Similar to the ototoxic mechanism of platinum-based drugs, 
aminoglycosides induce excessive formation of free oxygen species followed by apoptosis 
of sensory hair cells [10, 15]. The aminoglycoside-induced hearing loss is bilateral and 
permanent and starts in the high frequencies. Precisely because of its ototoxic proper-
ties, gentamicin is frequently used for the treatment of Ménière’s disease in the form of 
intratympanic injections to deplete the vestibular hair cells and thus, to prevent frequent 
vertigo attacks.
Of note: About 30% of the world population is infected with Mycobacterium  tuberculosis [16]. The 
treatment of tuberculosis (especially that caused by multiple-drug resistant Mycobacterium 
tuberculosis) includes intravenous administration of so-called ond-line antibiotics–amikacin, 
kanamycin and streptomycin–leaving at least 20% of the patients with  serious permanent 
hearing impairment [17].
Loop diuretics are a group of drugs that inhibit renal reabsorption of sodium, chloride and 
potassium. They are often used to treat kidney insufficiency or heart failure. Loop diuretics 
include furosemide, bumetanide, ethacrynic acid and torsemide. Their ototoxic mechanism 
involves inhibition of potassium resorption occurring in the stria vascularis and consequent 
decrease in the endocochlear potential [18]. The hearing loss induced by loop diuretics is 
bilateral and usually reversible; however, since loop diuretics are known to synergize with 
platinum-based drugs or with aminoglycosides in their ototoxic action, in patients receiving 
drugs from both groups, loop diuretics may worsen the degree of permanent hearing loss 
[19–21].
There is a growing number of case reports and larger studies indicating that the family 
of ototoxic drugs is growing and embraces newly developed medications. Although the 
ototoxic properties of several pharmacological drugs were recently compiled in an excel-
lent review written by Cianfrone et al. [22], the clinical information changes and requires 
update.
In this chapter, we review selected group of frequently used, contemporary pharmacological 
drugs (phosphodiesterase-5 blockers and antiviral drugs (see Table 1), painkillers and immu-
nosuppressants) in aspect of audiologically important adverse reactions including hearing 
loss and tinnitus.
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The class of 
medication
Type of report Presence 
of 
tinnitus
Type of hearing 
loss
Measuring method Reversibility 
of hearing loss
References
PDE5 
inhibitors
Case report 
(1 subject)
Not 
stated
Profound 
bilateral 
sensorineural 
hearing loss
Pure tone 
audiometry; 
impedance 
audiometry; 
stapedial reflex 
absent on both sides
No [23]
Prospective study 
(21 subjects)
Not 
stated
Unilateral 
sensorineural 
hearing loss 1 h 
after injection of 
drug
Pure tone 
audiometry
Yes [24]
Analysis of 47 
case reports 
(pharmacovigilance)
Not 
stated
Unilateral 
or bilateral 
sensorineural 
hearing loss
Not stated In some cases, 
yes; in others 
long-term 
impairment
[26]
Case report 
(2 subjects)
Yes Unilateral 
sensorineural 
hearing loss
Pure tone 
audiometry, ABR
In one case, yes [27]
Interferons Prospective study 
(before/after) 49 
subjects
Yes Sensorineural 
hearing loss
Pure tone audiometry, 
tympanometry 
(normal)
Yes [30]
Case report 
(3 subjects)
Yes Unilateral 
sensorineural 
hearing loss
Pure tone 
audiometry
Yes (2 cases), 
no (1 case)
[31]
Prospective study 
(before/after) 73 
subjects
Yes Sensorineural 
hearing loss
Pure tone 
audiometry
Yes [31]
PEG 
interferons
Prospective study 
(before/after) 21 
subjects
Not 
stated
None found Pure tone 
audiometry, DPOAE
Not applicable [35]
Case report 
(1 subject)
Not 
stated
Unilateral 
hearing loss
Not stated Yes [36]
Case report 
(1 subject)
Yes Unilateral 
hearing loss
Not stated No [37]
Case report 
(6 subjects)
Yes 
(4 of 6)
Five subjects 
developed 
unilateral and 
one bilateral 
sensorineural 
hearing loss
Pure tone 
audiometry
No 
improvement 
in three 
cases, some 
improvement 
in two cases, no 
data in one case
[38]
Although in the industrialized countries, the hepatitis C and B therapy with pegylated or non-pegylated interferons and 
ribavirin is being replaced by other pharmacological regimes, one should not ignore the fact that not all countries and 
hospitals have adopted the new routine and that the interferons are still in use, possibly contributing to drug-related 
hearing loss.
Table 1. Summary of clinical reports describing hearing loss in PDE5- and interferon-treated patients.
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2. Phosphodiesterase-5 (PDE5) inhibitors
PDE5 inhibitors block the phosphodiesterase-5 in the smooth muscle cells lining the blood 
vessels in the cardiovascular system. Phosphodiesterase-5 degrades cyclic GMP, regulating 
smooth muscle tone. The first PDE5 inhibitor–sildenafil–was introduced in the market in 1998 
under the name Viagra. PDE5 inhibitors are used for the treatment of erectile dysfunctions 
and for pulmonary artery hypertension.
In the year 2007, an alarming report was published by Mukherjee and Shivakumar, in which 
a case of bilateral profound sensorineural hearing loss was described in 44-year-old man who 
took 50 mg/day of sildenafil for 2 weeks [23]. Based on that report, FDA issued a warning 
about possible sudden hearing loss among users of PDE5 inhibitors.
Over the past 10 years, evidence suggesting negative influence of PDE5 inhibitors on hearing 
has accumulated. In a clinical study, Okuyucu et al. [24] reported significant but reversible 
unilateral hearing loss in four of 18 patients taking PDE5 inhibitors. The hearing loss affected 
the right ear at 10,000 Hz (p = 0.008).
Much larger epidemiological study published 1 year later by McGwin [25] evaluated the rela-
tionship between hearing loss and the use of PDE5 inhibitors in a population-based sample. 
This USA-based study was designed using self-reported hearing impairment and PDE5i use 
and included over eleven thousand men who were 40 years or older. Results of this study 
indicated that men with hearing loss are more than twice as likely to use PDE5 inhibitors, 
when compared with those not reporting hearing loss. However, no causal relationship could 
be established in that study.
In 2011, Khan et al. [26] published a report based on data provided by pharmacovigilance 
agencies Europe, the Americas, East Asia and Australasia, and on published reports. The 
authors identified among PDE5 inhibitor users 47 cases of sensorineural hearing loss, most 
of them unilateral. Almost 70% of the subjects (mean age 56.6 years, men-to-women ratio 7:1) 
reported hearing loss within 24 h after ingestion of PDE5 inhibitors.
In 2012, unilateral sudden sensorineural hearing loss affecting two male PDE5 inhibitor users 
(age 37 and 43) was described by Barreto and Bahmad [27]. Unfortunately, neither the time 
after the hearing loss has occurred nor the dosage of PDE5 inhibitors was stated. In addition 
to the hearing loss, both patients were affected by vertigo and tinnitus. After combination 
therapy consisting of steroids administered orally and intratympanically, one of the patients 
recovered partially, whereas the other one was left with permanent profound sensorineural 
hearing loss.
The causal relationship between the PDE5 inhibitors and (sudden) sensorineural hearing loss 
remains to be confirmed using experimental models. Au and colleagues using the animal 
model (C57BL/6J mice) and sildenafil (Viagra) were unable to find the differences in hearing 
thresholds between the drug- and placebo-treated animals [28]. However, other functional 
studies in mice with the use of osmotic pumps for drug release demonstrated that the inner 
ear of animals exposed to sildenafil reacted with hydrops [29].
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The epidemiological and case report data indicate that PDE5 inhibitors may have general 
negative impact on hearing. Moreover, PDE5 inhibitors may induce sudden sensorineural 
hearing loss that in some cases can be successfully treated with corticosteroids; in some other 
cases, the patients recover without any treatment; and lastly, it can also leave patients with 
permanent hearing impairment.
3. Antiviral medications
3.1. Interferons
Interferons (IFN) are a group of naturally occurring proteins that are released by several cell 
types in response to infection or tumors. There are three classes of interferons: type I, type II 
and type III. Type I interferons include IFN-alpha and IFN-beta. Synthetic and recombinant 
interferons, alpha and beta, have been used for therapy of viral infections with hepatitis C or 
B virus. In addition, IFN-beta can be used to treat multiple sclerosis.
One of the first reports associating interferon treatment with hearing loss was published in 
1994 [30]. In that report, a group of 49 patients (32 men and 17 women, mean age 48.6, age 
range 23–67) receiving various brands of interferons for chronic hepatitis B or C were assessed 
with pure tone audiometry before the onset of treatment and then in consecutive 1-week 
interval. In case of IFN-alpha, the drug was administered i.m. each day for 2 weeks and then 
three times a week for 14–22 weeks. In case of IFN-beta, the drug was administered i.v. daily 
for 6 weeks. The study demonstrated that 45% (22 patients) developed auditory dysfunction: 
14 patients (29%) reported having tinnitus and 18 patients (35%) were diagnosed with sud-
den sensorineural hearing loss. More than half (56%) of the patients treated with interferon-
beta (total of 27 subjects) developed auditory disability with unilateral or bilateral hearing 
loss affecting various frequencies diagnosed in 11 patients (41%). In the group treated with 
IFN-alpha (total of 22 subjects), seven developed unilateral hearing loss affecting 8000 Hz. 
Progressive hearing loss leads in two cases to withdrawal from therapy. There was no associa-
tion between the clinical parameters such as proteinuria, leucopenia, liver functions and the 
hearing loss. Interestingly, all patients recovered within 2 weeks after finishing the interferon 
treatment.
Published 1 year later, prospective audiological study of 73 patients treated with IFN-alpha 
or IFN-beta for hepatitis confirmed the above observations, including the hearing loss exclu-
sively affecting 8000 Hz in patients receiving IFN-alpha [31]. There was, however, one differ-
ence: in the larger sample studied, the hearing abilities of one patient have not recovered after 
discontinuation of therapy. Later, studies confirmed majority of these observations [32] and 
most importantly the general reversibility of ototoxic effects of IFN-alpha [33].
Interesting mechanistic insights of IFN-alpha-induced ototoxicity were delivered from studies 
using mouse model [34]. There was an elevated ABR threshold in mice treated with IFN-alpha 
as compared to untreated control group. Moreover, histological findings of cochleae dissected 
from experimental animals indicated abnormalities in the number (lower) and appearance 
(cytoplasmic vacuolization) of the spiral limbus fibroblasts in the IFN-alpha-treated mice. 
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These findings point to direct negative effect of IFN-alpha on cochlear biology, which may 
result in the hearing loss.
3.2. Pegylated interferons and ribavirin
Pegylated interferons are chemically “improved” interferons bound to polyethylene glycol 
(PEG). Pegylation assures longer half-time of interferons in the body. There are three groups 
of pegylated interferons available in the market–pegylated interferon-alpha-2a (PEG-IFNa2a), 
pegylated interferon-alpha-2b (PEG-IFNa2b) and pegylated interferon-beta-1a.
Ribavirin is a guanosine analog (nucleoside inhibitor) that stops viral RNA synthesis. It is 
used to treat various viral hemorrhagic fevers, and it is the only known drug against rabies. 
Although new therapeutic approaches are being introduced on the healthcare market for the 
treatment of hepatitis C (e.g., protease inhibitor telaprevir or boceprevir), ribavirin in com-
bination with PEG-IFN-alpha is still a part of the current standard of care (SOC) therapy in 
some countries and it is also included in the new therapeutic regime.
Therapeutic use of PEG-IFN and ribavirin in hepatitis C infections induces similar otological 
effects as the therapy with non-pegylated interferons only. However, there is one major dif-
ference: the hearing abilities do not recover in the majority of cases. Although some reports 
describe no hearing disabilities [35] or sudden unilateral sensorineural hearing loss resolving 
spontaneously within 2 weeks after the end of treatment [36], some other demonstrate that 
patients may develop irreversible unilateral hearing loss [37] or irreversible unilateral pan-
tonal hearing loss (measured by pure tone audiometry) and tinnitus [38].
3.3. Inhibitors of viral reverse transcriptase
According to the United Nations AIDS organization, approximately 36.7 million people world-
wide are infected with the HIV virus. The patients with HIV are treated with drugs that inhibit 
the virus proliferation. Since HIV virus uses very unique enzyme to copy its genome, this 
enzyme–reverse transcriptase–is a pharmacological target of anti-HIV therapy. The unique thing 
about the HIV therapy is that it should never be stopped, even if the viral load is undetectable.
The discovery and the beginning of clinical application of reverse transcriptase inhibitors 
date back to the eighties last century. The first reports about their negative effect on hearing 
appeared some 10 years later and ever since conflicting conclusions are being drawn from 
several studies. In some studies, authors found the hearing loss among 30% of HIV patients 
taking the reverse transcription inhibitors [39–41], whereas in other studies, no association 
between audiological impairment and antiviral medication was found [42, 43]. Various inclu-
sion criteria, diverse outcome measure methods, sample size and many other factors could 
contribute to these dissimilar results.
In the controlled environment of experimental laboratory, the results look much more uni-
form and point at universal ototoxicity of all types of reverse transcriptase inhibitors that are 
on the market, as measured by the viability of auditory epithelial cell line exposed to various 
concentrations of 14 types of pharmacological reverse transcription inhibitors as single agents 
and in combination, as used in the clinics [44].
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4. Paracetamol (acetaminophen) and hydrocodone
Paracetamol, also known as acetaminophen (in the USA and Canada) or APAP, is the most 
commonly used pain killer in North America and Europe. It inhibits selectively cyclooxy-
genase-2 (COX-2) and may also exert other pain-relieving functions. Recent studies on self-
reported professionally diagnosed hearing loss and use of analgesics indicated that regular 
use of paracetamol significantly increases the risk of hearing loss in men [45] and women 
[46]. The large size of samples with which the studies were performed (26,917 men and 62,261 
women) makes both studies particularly credible.
The main conclusion from this study was that the long-term use of paracetamol (acetamino-
phen) increases the risk of developing hearing loss in men and women.
The mechanism of paracetamol-induced hearing loss was experimentally addressed in vitro 
[47]. The authors demonstrated that in the mouse auditory epithelium cell line, paracetamol 
and its metabolite NAPQI (N-acetyl-p-benzoquinoneimine) induce ototoxicity by causing oxi-
dative stress as well as endoplasmic reticulum (ER) stress. These basic research results pos-
sibly explain the ototoxicity seen in people who regularly consume paracetamol. The question 
about usage of paracetamol and its frequency should be included in the surveys/question-
naires of patients with otologic and audiologic considerations.
Hydrocodone is a semi-synthetic opioid used for pain therapy and in common anti-cough 
medications. Hydrocodone is often prescribed in combination with paracetamol. In a report 
describing 12 patients with a history of hydrocodone overuse and progressive irreversible sen-
sorineural hearing loss, the authors implicated nonresponsiveness of this type of hearing loss 
to corticosteroid therapy [48]. The authors reported that seven of eight patients who under-
went consecutive cochlear implantation benefited from this type of auditory rehabilitation. 
Similar recent case report described a patient with unilateral hearing loss attributed to abuse 
of hydrocodone and paracetamol [49]. Also this patient was treated with cochlear implant.
The information delivered from the in vitro model with auditory epithelial cell line suggested 
that the combination of hydrocodone and paracetamol results in ototoxicity not due to hydro-
codone but rather due to paracetamol [50]. The authors suggested that the contribution of 
hydrocodone to clinically seen ototoxicity may lay in hydrocodone assisting the addiction to 
the drug combination.
5. Methadone
Methadone is an opioid drug for treating pain. In addition, it is used for therapy of people 
addicted to opioids.
In the year 2014, about 7 million US citizens were abusing prescription drugs (source: National 
Center for Health Statistics). One of these drugs is methadone. Six recent case reports exposed 
an unknown before side effect of methadone abuse–the hearing loss [51–55]. The patients 
described in reports were young (age range 20–37) and were admitted to the hospitals because 
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of methadone overuse. In all reported cases, the patients were deaf upon awakening (one 
perceived tinnitus), and in four of six cases, hearing loss was only temporary condition. The 
remaining two patients were unfortunately left with severe sensorineural hearing loss for the 
remaining observation time (2 and 9 months).
6. Immunosuppressant calcineurin inhibitors 
(cyclosporine A and tacrolimus)
Since the beginning of transplantology in the sixties, several people with incurable diseases of 
liver, kidney and other organs received the donor tissues as therapeutic procedure. This type 
of therapy is combined with an inevitable immune reaction against the non-self tissue. To pre-
vent these reactions, immunosuppressants are used. Among them, cyclosporine A and tacro-
limus (FK506) are commonly used to prevent graft rejection reaction. Both drugs decrease in 
various ways the activation of lymphocytes T and thus inhibit the graft rejection process. The 
immunosuppressants must be taken continuously.
Rifai et al. [56] performed a large study involving 521 liver transplant patients. The study was 
based on self-reported hearing loss and showed that of 521 individuals, 141 (27%) developed 
hearing loss following transplantation, particularly in those patients who were receiving 
tacrolimus as principal immunosuppression. This study was followed by recent trial, where 
instead of self-reported hearing loss, audiometric measurements were performed [57]. Of 70 
liver transplant patients included in that study, 32 reported hearing loss and tinnitus fol-
lowing the transplantation. The types of hearing loss included sudden hearing loss and pro-
gressive hearing loss, which developed more than 3 years after transplantation. Audiometry 
confirmed the patients’ reports and identified 12 patients with mild, 28 with moderate and 25 
with severe hearing loss following the transplantation. The association between tacrolimus 
and hearing loss was seen again in this study.
Another group of transplant patients is the renal transplant group. Kidney transplantation 
is a surgical procedure performed since the mid-fifties last century; however, postsurgical 
survival was very low, because of the graft rejection [58]. The introduction of cyclosporine A 
in the eighties significantly improved the post-transplant survival rate but brought another 
type of problems, namely adverse reactions such as hearing loss. Renal patients are known to 
often have hearing impairments [59], and it was shown that the renal transplantation restores 
the hearing abilities, when measured 1 year after surgery. However, some renal transplant 
patients who are on a long-term immunosuppressant therapy such as cyclosporine A or tacro-
limus develop hearing disabilities including sudden sensorineural hearing loss [60–62] or a 
progressive hearing loss [63].
Particularly, worrying tendency is seen among the pediatric renal transplant patients. A pro-
spective study of 27 children (mean age 14) with normal hearing prior to kidney transplanta-
tion determined after a mean follow-up of 30 months that 17 children developed sensorineural 
hearing loss [60]. Two of 17 children were diagnosed with sudden hearing loss and the rest of 
the group with a progressive bilateral hearing loss.
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It is likely that the ototoxic effect of immunosuppressants depends on the length of time of 
intake. Groups studying noise-induced hearing loss have successfully used cyclosporine A 
and tacrolimus to protect the auditory epithelium in mice from the noise-induced injury [64]. 
However, the dosage was single and not–like in the case of transplant patients–years long.
The treatment of hearing impairment occurring in organ transplant recipients includes hear-
ing aids and cochlear implantation [65]. However, one should not ignore the fact that these 
patients are immunocompromised, and therefore, the risk of wound infection after CI should 
be taken under consideration during postsurgical management.
7. Mitochondrial toxicity: common denominator of ototoxic drugs
The auditory system requires a lot of energy produced in mitochondria [66–69]. Mitochondrial 
pathologies induced by genetic mutations are often associated with hearing loss [70–72]. 
Similarly, substances known to damage mitochondria such as aminoglycosides or cisplatin 
are known as ototoxic and contribute significantly to the hearing loss and tinnitus [73].
The substances listed in the present chapter can all damage the mitochondria. The damaging 
mechanism varies, and for instance, IFN-alpha impairs the transcription of mitochondrial 
DNA, whereas nucleoside analogues impair the replication of mitochondrial DNA [74]. In 
agreement with this, severe mitochondrial toxicity manifested by hyperlactatemia and pan-
creatitis was described in some cases involving patients with HIV/hepatitis C virus treated 
with pegylated interferon and ribavirin [75]. Paracetamol was also shown to have negative 
effect on mitochondria by inducing overproduction of reactive oxygen species (ROS) and 
inducing endoplasmic reticulum stress [47, 76]. Methadone was shown to impair synthesis of 
mitochondrial ATP leading to bioenergetics crisis of the affected organism [77]. The reverse 
transcriptase inhibitors used to slow down the replication of HIV virus were likewise demon-
strated to induce mitochondrial toxicity [78, 79]. Lastly, cyclosporine A was shown to inhibit 
adenine nucleotide net transport into the mitochondria [80], whereas tacrolimus was associ-
ated with decreasing the levels of oxidative phosphorylation in mitochondria [81].
Since the negative effect of various drugs on mitochondria likely results in a damage of hear-
ing, it is plausible that the mitochondria-supporting substances (such as coenzyme Q10, vita-
min B12 with folic acid, sirtuin and many others) given as auxiliary therapy could protect 
the sense of hearing in patients with hepatitis, HIV, transplant patients or painkiller or PDE5 
inhibitor users. In fact, targeting mitochondria is becoming increasingly popular [82], and 
there were some successful attempts in treatment of hearing conditions using mitochondrial 
supplements [83–89].
8. Conclusions
The appearance of new drugs to treat ever more conditions is an inevitable and welcomed 
progress of medical and pharmaceutical sciences. However, assuring the drug safety in terms 
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of hearing disability is difficult, and it often requires very long and regular intake periods, 
which are outside of regular phase I, II or III clinical trials. As for the duration of phase IV 
(the postmarketing surveillance trials), which is usually set for 2 years, perhaps it could be 
extended specifically for the monitoring of audiological conditions.
The ototoxicity of prescription or over-the-counter drugs is a global problem. Collaboration 
between audiologists or otologists and other healthcare providers is necessary to protect the 
patient’s auditory health. Auditory consultations ought to be a routine during the treatment 
of patients with viral hepatitis C or B receiving interferons and ribavirin or HIV-positive 
individuals taking anti-reverse transcriptase drug cocktail. Moreover, patients undergoing 
solid organ transplantation should be audiologically monitored. The option of audiological 
care for children treated for any of the above infectious diseases or undergoing transplan-
tation should be presented to their parents. Lastly, frequent users of painkillers and recre-
ational drugs should be informed about the risks of the medications they are reaching for 
every day.
During the unavoidable drug therapies, preventive means such as mitochondrial protec-
tion and supplementation during the drug treatment and audiological monitoring as well 
as fitting the patients with hearing aids or cochlear implants, could help to keep the hearing 
healthy or at least to restore it to some degree.
The good condition of hearing is as important as that of heart, lung or other organs. Informing 
the community about ototoxicity and keeping up to date with the case reports and other sci-
entific communications may help to save the sense of hearing.
Glossary of terms
Cyclosporine A  Fungal metabolite that suppresses immune reaction. It inhib-
its the activation of lymphocytes T by binding to cyclophilin 
and inhibiting calcineurin
Endocochlear potential  Voltage of +80mV in the scala media, generated by the stria 
vascularis, essential for the auditory transduction
Interferon (IFN)-alpha  Small signaling protein produced and released mainly by 
white blood cells in response to viral infection
Interferon (IFN)-beta  Small signaling protein produced and released mainly by 
fibroblasts in response to viral infection
Intratympanic injections Injections through the eardrum into the middle ear cavity
Mycobacterium tuberculosis Infectious microorganism causing tuberculosis
Nucleoside  Glycosylamine (e.g., cytidine, uridine, adenosine, guanosine 
or thymidine), primary DNA or RNA molecule. Also known 
as nucleotide without phosphate group
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Phosphodiesterase-5 (PDE5)  Enzyme that catalyzes the hydrolysis of cyclic GMP and 
regulates tonus of smooth muscle cells
PDE5i Phosphodiesterase-5 inhibitors
Polyethylene glycol (PEG)  Polymer of ethylene oxide. PEG can be bound to proteins, 
therefore slowing their decay time in the body
Protease inhibitor  Inhibitor of enzymes that degrade proteins. Viral proteases 
are essential for viruses to complete their life cycle
Reverse transcriptase (RT)  Enzyme that synthesizes DNA using as a template RNA, a 
process called reverse transcription. This process is specific 
for viral replication and is used for instance by HIV virus
Tacrolimus (FK-506)             Bacterial derivative isolated from Streptomyces tsuku-
baensis. Tacrolimus inhibits activation of lymphocytes T via 
inhibiting calcineurin. Similar but not identical in action to 
cyclosporine A
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